No More Licensing: NY Biotech Company Zentalis Raises US$20M To Fund Chinese Venture

Zentalis

The joint venture Zentera will develop and commercialize Zentalis’ pipeline candidates in China

New York-headquartered clinical-stage biopharmaceutical company Zentalis Pharmaceuticals has closed a Series A round at $20 million to fund the establishment of joint venture Zentera Therapeutics, the company announced in a statement earlier this week.

Zentalis will hold majority stakes in Shanghai-headquartered biopharma venture Zentera, and Chairman and CEO of Zentalis Anthony Sun, MD, will also serve as Zentera’s chief executive, the statement added.

Sun pointed out in the statement that the launch of Zentera served as a milestone for Zentalis’ global clinical development strategy. He added that the company was also building a management team of ‘seasoned professionals’ in China.

“As the second-largest pharmaceutical market in the world, establishing a joint venture in China is the first step toward advancing our product candidates on a global scale,” he noted.

The financing round was led by Hong Kong-based equity investment firm Tybourne Capital Management (TCM), with participation from healthcare fund OrbiMed Asia, the statement said.

Managing Director and Co-Head of Private Equity at TCM, Bosun Hau said in the statement, “Over the past few years, we have watched Zentalis’ remarkable clinical progress in developing potentially best-in-class candidates for patients with cancer. We are pleased to work with Zentera, as we believe these therapies will greatly benefit patients internationally.”

The statement noted that the Series A would help fund the development and commercialization of three cancer therapies from Zentalis, which focuses on small molecule therapeutics targeting cancer pathways, as well as future candidates from the company in China.

Pipeline oral candidates that Zentera will be developing in China are selective estrogen receptor degrader (SERD) ZN-c5 for breast cancer, DNA damage response protein WEE1 inhibitor ZN-c3 for solid tumors, and B-cell lymphoma 2 (BCL-2) inhibitor ZN-d5 for hematologic malignancies.

Of these, both ZN-c5 and ZN-c3 have reached the initial clinical trial stage. Zentalis has applied for Investigational New Drug (IND) permissions for ZN-d5 with the United States (U.S.) Food and Drug Administration, and plans to launch the Phase 1 trial of ZN-d5 in the first half of 2021.

Zentalis also has a fourth pipeline candidate ZN-e4, an oral mutant epidermal growth factor receptor (EGFR) small molecule inhibitor. Rights to develop and commercialize this particular candidate have been licensed to California-based specialty pharmaceutical company SciClone Pharmaceuticals in China, South Korea, Taiwan and Vietnam.

Zentalis made headlines earlier this year when it went public with an initial public offering (IPO) in the midst of the COVID-19 pandemic, which crushed global markets and forced many to defer planned IPOs.

The IPO grossed $190 million, with 10,557,000 shares offered at $18 per share. After deduction of underwriters’ options, its net amount at $165 million still surpassed the $100 million figure it had filed with the U.S. Securities and Exchange Commission prior to the IPO.

In December 2019, Zentalis had also raked in $85 million in a Series C financing round, raised only three months before going public. Matrix Capital, Viking Global Investors, Redmile Group, Farallon Capital, Perceptive Advisors, Surveyor Capital and Eventide Asset Management participated in the round.

Header image by Anna Shvets from Pexels

SHARE THIS STORY

Share on facebook
Share on twitter
Share on linkedin
Share on email

RELATED POSTS

Transparency in the Post FTX World What is Proof of Reserve

Transparency in the Post FTX World: What is Proof of Reserve?

In November this year, two big league crypto businesses, FTX and BlockFi, filed for bankruptcy. FTX had a death spiral after news broke out that the Sam Bankman-Fried-owned exchange had used customer funds to make risky bets through his hedge fund Alameda Research. On the other hand, FTX was closely associated with BlockFi, with them having signed a loan agreement with each other and BlockFi holding US$355 million in digital assets on FTX.

How Do Recommendation Engines Work

How Do Recommendation Engines Work?

Picture this: You just finished a film on Netflix and want to follow it up with something similar. Luckily, Netflix comes to the rescue and gives you the perfect suggestions to continue your weekend movie binge. This isn’t just a hypothetical scenario but something a lot of people actually go through.

Quantum Computing Has a Cybersecurity Problem. Here’s How Experts Are Solving It

Quantum Computing Has a Cybersecurity Problem. Here’s How Experts Are Solving It

In 2019, Google used its quantum computer, the Sycamore machine, to prove that quantum computers can solve a problem in mere minutes. Experts working on the quantum computer found that their system could execute a calculation in 200 seconds, whereas a standard computer would take 10,000 years to complete. What on earth is this powerful tool?

Here Are Some Alternative Sites People Are Jumping To

Musk May Have Killed Twitter: Here Are Some Alternative Sites People Are Jumping To

Ever since Elon Musk purchased the social networking site Twitter for US$40 billion, things haven’t been looking too good for the company’s future. Not only did Musk fire over 50% of the employees soon after stepping on board as the new chief executive officer, but he also intends to allow maximum freedom of speech. This can end up making Twitter a cesspool of racism and misogyny, as well as other forms of hate speech.

How Do Venture Capitalists Choose Which Project to Invest In?

How Do Venture Capitalists Choose Which Project to Invest In?

For those in the entrepreneurial space, raising funds can be very challenging. Not only is it difficult to find the right investor for your startup, but it is also hard to convince said investor to put money into your venture. With over 75% of venture-backed companies failing, the venture capitalist (VC) you approach is taking a serious risk when putting their money into your startup.

CEOs That Crashed and Burned in 2022

CEOs That Crashed and Burned in 2022

As 2022 draws to a close, it is time to sit back and reflect on events that have unfolded this year—the good, the bad and the ugly. We saw massive layoffs in the tech space and a devastating crypto market crash with one crypto company going down after another. You must have seen article after article talking about the situation with Luna and Celsius as well as the recent bankruptcy filings of FTX and BlockFi.